In Novo Nordisk A/S’s home country of Denmark, the popularity of weight-loss drugs is fueling economic growth, but local ...

Telehealth company Hims & Hers is facing a growing number of U.S. investor lawsuits after Novo Nordisk's decision last month ...

Key Points Hims & Hers Health is entering the Canadian market.The company will offer a generic version of semaglutide in the ...

Novo Nordisk NVO generates most of its revenues from the sales of its blockbuster GLP-1 injections, Ozempic for type II ...

The partnership between the Danish pharmaceutical giant and the splashy telehealth firm Hims & Hers was strained from the ...

Novo Nordisk's recent financial results and clinical progress haven't impressed Wall Street. Investors looking to strike ...

Novo Nordisk A/S (NYSE: NVO) is one of the high-margin pharma stocks to buy now. Berenberg has reaffirmed its Hold rating on ...

In what Science magazine has dubbed “Novo Nordisk’s Canadian Mistake,” Ozempic is soon to come off patent in Canada, opening ...

Find insight on Novo Nordisk, European drug exports, and more in the latest Market Talks covering Health Care.

Biopharmaceutical company Biocon is planning to submit a request for approval of generic copies of the blockbuster ...

In an echo of the pattern laid last year, following a record-high outlay at the very beginning of the year, TV drug ad ...

Some health experts view GLP-1s as a promising option for PCOS, which lacks a standard treatment and affects millions of ...